Praluent sales to continue as court orders new trial

An appellate court decision will allow hypercholesterolemia drug Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to remain on the market, pending the outcome of a new trial ordered by the court to settle patent litigation with Amgen Inc. (NASDAQ:AMGN).

The U.S. Court of Appeals for the Federal Circuit tossed out a district court's injunction blocking U.S. sales of Praluent and determined that the district court's proceedings were conducted in error. CAFC remanded the case to the U.S. District Court for the District of Delaware and ordered a new trial...